Sergey Yurasov
Chief Tech/Sci/R&D Officer chez BLACK DIAMOND THERAPEUTICS, INC.
Profil
Sergey Yurasov is currently the Chief Medical Officer at Black Diamond Therapeutics, Inc. He previously held positions as Clinical Director-Oncology & Pharma Research at Hoffman-La Roche, Inc., Associate Vice President-Global Medicine Science at ImClone LLC, Assistant Professor-Clinical Investigation at The Rockefeller University, Chief Medical Officer & SVP-Clinical Development at Immune Design Corp., and Senior Vice President-Clinical Development at Clovis Oncology, Inc. He also served as the Chief Medical Officer at Nuvation Bio, Inc. from 2019 to 2022.
Dr. Yurasov holds a doctorate degree from the Russian State Medical University and the Research Institute for Pediatric Oncology.
Postes actifs de Sergey Yurasov
| Sociétés | Poste | Début |
|---|---|---|
| BLACK DIAMOND THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/06/2022 |
Anciens postes connus de Sergey Yurasov
| Sociétés | Poste | Fin |
|---|---|---|
| NUVATION BIO INC. | Chief Tech/Sci/R&D Officer | 01/02/2022 |
| IMMUNE DESIGN CORP | Chief Tech/Sci/R&D Officer | 02/04/2019 |
| The Rockefeller University | Corporate Officer/Principal | - |
| Hoffman-La Roche, Inc. | Corporate Officer/Principal | - |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Corporate Officer/Principal | - |
Formation de Sergey Yurasov
| Russian State Medical University | Doctorate Degree |
| Research Institute for Pediatric Oncology | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BLACK DIAMOND THERAPEUTICS, INC. | Health Technology |
| NUVATION BIO INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
Immune Design Corp.
 Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
| Hoffman-La Roche, Inc. | Health Technology |
